Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India.
Fundam Clin Pharmacol. 2013 Feb;27(1):1-20. doi: 10.1111/j.1472-8206.2012.01051.x. Epub 2012 Jul 4.
Cardiovascular diseases (CVDs) place a heavy burden on the economies of low- and middle-income countries. Comprehensive action requires combining approaches that seek to reduce the risks throughout the entire population with strategies that target individuals at high risk or with established disease. Small interfering RNA (siRNA) as a functional mediator for regulation of gene expression has been evaluated for potential therapeutic targets for the treatment of various cardiovascular diseases such as hypertension, atherosclerosis, heart failure etc. The present review attempts have been made to provide a brief outline of the current understanding of the mechanism of RNAi and the delivery system and describe the therapeutic application of siRNAs and their potential for treating CVDs which are taking a heavy toll on human life.
心血管疾病(CVDs)给中低收入国家的经济带来了沉重负担。全面的行动需要结合旨在降低整个人群风险的方法,以及针对高风险人群或已患疾病人群的策略。小干扰 RNA(siRNA)作为一种调节基因表达的功能介质,已被评估为治疗各种心血管疾病(如高血压、动脉粥样硬化、心力衰竭等)的潜在治疗靶点。本综述旨在简要概述 RNAi 的作用机制和递药系统的当前认识,并描述 siRNA 的治疗应用及其在治疗对人类生命造成沉重负担的 CVDs 方面的潜力。